首页> 外文期刊>Environmental health perspectives. >The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. Phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol.
【24h】

The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. Phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol.

机译:经合组织计划验证大鼠Hershberger生物测定法,以筛选化合物的体内雄激素和抗雄激素反应。阶段1:使用有效的激动剂和有效的拮抗剂来测试标准化方案。

获取原文
获取原文并翻译 | 示例
           

摘要

The Organisation for Economic Cooperation and Development (OECD) has completed phase 1 of the Hershberger validation intended to identify in vivo activity of suspected androgens and antiandrogens. Seventeen laboratories from 7 countries participated in phase 1, and results were collated and evaluated by the OECD with the support of an international committee of experts. Five androgen-responsive tissues (ventral prostate, paired seminal vesicles and coagulating glands, levator ani and bulbocavernosus muscles, glans penis, and paired Cowper's or bulbourethral glands) were evaluated. The standardized protocols used selected doses of a reference androgen, testosterone propionate (TP), and an antiandrogen, flutamide (FLU). All laboratories successfully detected TP-stimulated increases in androgen-responsive tissue weight and decreases in TP-stimulated tissue weights when FLU was co-administered. The standardized protocols performed well under a variety of conditions (e.g., strain, diet, housing protocol, bedding). There was good agreement among laboratories with regard to the TP doses inducing significant increases in tissue weights and the FLU doses decreasing TP-stimulated tissue weights. Several additional procedures (e.g., weighing of the dorsolateral prostate and fixation of tissues before weighing) and serum component measurements (e.g., luteinizing hormone) were also included by some laboratories to assess their potential utility. The results indicated that the OECD Hershberger protocol was robust, reproducible, and transferable across laboratories. Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5alpha-reductase inhibitor, and chemicals having no androgenic activity.
机译:经济合作与发展组织(OECD)已完成Hershberger验证的第一阶段,该阶段旨在确定可疑雄激素和抗雄激素的体内活性。来自7个国家的17个实验室参加了第一阶段,经合组织在国际专家委员会的支持下对结果进行了评估和评估。评估了五种雄激素反应性组织(腹侧前列腺,成对的精囊和凝结腺,肛提肌和球海绵体肌肉,龟头阴茎和成对的考珀氏或膀胱神经管腺)。标准化方案使用选定剂量的参比雄激素,丙酸睾丸激素(TP)和抗雄激素,氟他胺(FLU)。当联合使用FLU时,所有实验室均成功检测到TP刺激的雄激素反应性组织重量增加和TP刺激的组织重量减少。标准化协议在各种条件下(例如劳损,饮食,住房协议,寝具)表现良好。关于TP剂量引起组织重量的显着增加和FLU剂量降低TP刺激的组织重量的实验室之间达成了很好的共识。一些实验室还包括一些其他程序(例如,称重背外侧前列腺并在称重之前固定组织)和血清成分测量(例如,黄体生成激素)以评估其潜在用途。结果表明,OECD Hershberger协议是可靠的,可重复的并且可以在实验室之间转移。根据此阶段1的验证研究,已对方案进行了完善,经合组织验证程序的下一阶段将使用选定剂量的弱雄激素激动剂,雄激素拮抗剂,5α-还原酶抑制剂和无雄激素活性的化学物质测试方案。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号